Compumedics (ASX:CMP) has delivered a strong first half performance in the 2026 financial year, marked by record sales orders, a substantial uplift in shipped revenue, and improving earnings momentum.
During the first half, Compumedics achieved record sales orders of $34.9 million, representing a 6 per cent increase on the prior corresponding period. This result reflects strengthening customer demand and improved sales conversion across the company’s core sleep and neurodiagnostic platforms. The uplift follows a targeted refocus of commercial activities in the United States, which has sharpened execution and increased emphasis on higher-probability opportunities.
Reported revenue for the half reached a record $30.8 million, up 32 per cent on the prior corresponding period.
Compumedics said it is advancing a $2 million per annum cost-out program designed to enhance margins while maintaining investment in priority growth initiatives. The program targets structural efficiency, reduced overhead intensity, and stronger capital discipline, with benefits expected to progressively build through the second half of 2026. As a result, the first half earnings, subject to audit, are expected to exceed $3 million.
The company has reaffirmed its full-year 2026 guidance, targeting revenue of $70 million and earnings of up to $9 million.
Commenting on the update, Executive Chairman Dr David Burton said the company is demonstrating clear strategic and operational momentum, highlighted by record first-half sales orders and strong shipped revenue growth.